Why was Viekira Pak discontinued?
Why was Viekira Pak discontinued?
This treatment has been discontinued. On October 22, 2015 the United States FDA issued a Drug Safety Warning that treatment with ombitasvir- Page 1/7 Page 2 paritaprevir-ritonavir and dasabuvir (Viekira Pak) can cause serious liver injury, mostly in patients with underlying advanced liver disease.
What kind of drug is Viekira Pak?
Viekira Pak (Viekira) is a combination antiviral medicine used to treat chronic hepatitis C virus (HCV) in adults. Viekira is sometimes given in combination with another antiviral medicine called ribavirin.
Is Daklinza available?
— All Daklinza tablets are now discontinued.
Is Zepatier still available?
Zepatier generic Zepatier contains two active drug ingredients: elbasvir and grazoprevir. Zepatier is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active drug in a brand-name medication.
What is Viekira Pak used for?
VIEKIRA PAK with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.
How much does Viekira cost?
The wholesale acquisition cost (WAC) for a 12-week treatment course with Viekira Pak is $83,319. The cost for a 24-treatment course with the Viekira Pak is $166,638.
What medications are in the Viekira Pak?
The Viekira Pak is an all-oral regimen comprised of four medications: ombitasvir, paritaprevir, ritonavir, and dasabuvir. This regimen can be used with or without ribavirin.
Is there a generic version of ribavirin?
The drug paritaprevir was discovered and developed as part of a collaborative effort between AbbVie and Enanta Pharmaceuticals. Ribavirin, which is recommended for use with the Viekira Pak in specific patient populations, is manufactured by multiple companies in the United States and is available in generic formulations.
Is ritonavir a CYP3A4 inhibitor?
Ritonavir is a potent inhibitor of CYP3A4 enzymes and is used as a pharmacologic booster for paritaprevir—it significantly increases peak and trough paritaprevir plasma concentrations, as well as the area under the curve of paritaprevir.
